Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations 

Rhea-AI Summary

Palvella Therapeutics (Nasdaq: PVLA) will host a live webcast conference call on February 24, 2026 at 8:00am ET to discuss topline results from the Phase 3 SELVA trial of QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations.

The company plans to release topline results at approximately 6:30am ET prior to the call. A replay will be available about 2 hours after the call and archived for 90 days in the Events & Presentations section of Palvella’s website.

Key Figures

Phase: Phase 3 QTORIN concentration: 3.9% Conference time: 8:00am ET +3 more

6 metrics

Phase Phase 3 SELVA trial of QTORIN rapamycin

QTORIN concentration 3.9% QTORIN rapamycin anhydrous gel formulation

Conference time 8:00am ET Conference call on February 24, 2026

Topline release time 6:30am ET Planned press release ahead of call

Webcast replay delay 2 hours Approximate time after call to replay availability

Replay archive period 90 days Duration webcast replay will be available

Market Reality Check

Price: $87.84 Vol: Volume 328,117 is slightl...

normal vol

$87.84 Last Close

Volume Volume 328,117 is slightly above the 20-day average of 295,915 (relative volume 1.11x) ahead of the Phase 3 topline discussion. normal

Technical PVLA trades above its 200-day MA of 60.92, indicating a pre-news upside trend into the SELVA Phase 3 catalyst.

Peers on Argus

PVLA gained 4.04% while close peers were mixed (e.g., SVRA up 2.15%, RIGL down 3...

1 Up

PVLA gained 4.04% while close peers were mixed (e.g., SVRA up 2.15%, RIGL down 3%, KROS down 2%), and only TYRA appeared in momentum scanners with a modest 1.95% move up, supporting this as a stock-specific setup.

Historical Context

5 past events · Latest: Feb 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 02	Scientific publication	Positive	+4.2%	Systematic review on topical statins in porokeratosis with future Phase 2 plans.
Jan 09	Corporate update	Positive	-5.1%	Broad 2026 outlook highlighting SELVA Phase 3 timing and NDA plans.
Jan 07	Leadership appointment	Positive	+11.7%	Appointment of SVP Medical Affairs to support QTORIN medical strategy.
Dec 16	Regulatory designation	Positive	+8.8%	FDA Fast Track designation for QTORIN rapamycin in angiokeratomas.
Dec 15	Phase 2 topline data	Positive	-9.7%	Positive Phase 2 TOIVA data in cutaneous venous malformations with FDA plans.

Pattern Detected

PVLA has often reacted strongly to pipeline and clinical updates, with a mix of aligned and divergent moves versus generally positive news.

Recent Company History

Over the past few months, Palvella has built a narrative around its QTORIN™ platform and late-stage pipeline. On Dec 15, 2025, positive Phase 2 TOIVA topline data for QTORIN rapamycin in cutaneous venous malformations saw a -9.74% move despite favorable efficacy and safety. Fast Track designation for angiokeratomas on Dec 16, 2025 and subsequent leadership and scientific updates in early 2026 produced moves from +4.19% to +11.72%. Today’s announcement of an upcoming Phase 3 SELVA topline call fits this ongoing clinical‑progress narrative.

Market Pulse Summary

This announcement schedules a conference call to discuss Phase 3 SELVA topline results for QTORIN™ 3...

Analysis

This announcement schedules a conference call to discuss Phase 3 SELVA topline results for QTORIN™ 3.9% rapamycin in microcystic lymphatic malformations, with data planned at 6:30am ET and a call at 8:00am ET. It follows prior Fast Track designation and positive Phase 2 data in related indications. Investors may watch how the topline results compare with earlier efficacy and safety signals and consider recent insider trading disclosures and concentrated institutional ownership when evaluating risk.

Key Terms

phase 3, qtorin™ 3.9% rapamycin anhydrous gel, microcystic lymphatic malformations, clinical trial, +1 more

5 terms

phase 3 medical

"to discuss topline results from the Phase 3 SELVA clinical trial assessing"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

qtorin™ 3.9% rapamycin anhydrous gel medical

"SELVA clinical trial assessing the efficacy and safety of QTORIN™ 3.9% rapamycin anhydrous gel"

A topical prescription medicine formulated as a gel that contains 3.9% rapamycin anhydrous, a drug that acts on cellular growth and inflammation pathways. Investors watch this product because its safety and effectiveness, regulatory status, patent protection and patient demand determine potential sales and profit—think of it as a new consumer product entering a regulated market where approval, market size and pricing drive commercial value.

microcystic lymphatic malformations medical

"for the treatment of microcystic lymphatic malformations."

Microcystic lymphatic malformations are noncancerous clusters of very small, fluid-filled channels in the skin or deeper tissues that form when the lymphatic system develops abnormally; think of them as a sponge of tiny blisters under or on the skin. They matter to investors because they create specific medical needs—diagnostics, procedures, and drug or device treatments—that drive research, regulatory review, potential market size, reimbursement decisions, and liability risks for healthcare companies developing solutions.

clinical trial medical

"Phase 3 SELVA clinical trial assessing the efficacy and safety"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

webcast technical

"Webcast conference call to take place tomorrow, Tuesday, February 24, 2026"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

Webcast conference call to take place tomorrow, Tuesday, February 24, 2026, at 8:00am ET

WAYNE, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will host a conference call and webcast tomorrow, Tuesday, February 24, 2026, at 8:00am ET to discuss topline results from the Phase 3 SELVA clinical trial assessing the efficacy and safety of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations. The Company plans to issue a press release sharing the topline results at approximately 6:30am ET tomorrow, prior to the start of the call.

Conference Call

To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" section of Palvella’s website. To access the call by phone, please use this registration link, and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the "Events & Presentations" section of the Company's website at www.palvellatx.com.

About Palvella Therapeutics

Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the topical treatment of disseminated superficial actinic porokeratosis. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).

QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.

Contact Information

Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com

Media
Marcy Nanus
Managing Partner, Trilon Advisors LLC
mnanus@trilonadvisors.com

FAQ

When will Palvella (PVLA) release topline SELVA Phase 3 results?

Palvella will release topline SELVA results on February 24, 2026 at approximately 6:30am ET. According to the company, the press release will precede the 8:00am ET conference call to discuss those topline efficacy and safety findings.

What time is the Palvella (PVLA) conference call to discuss QTORIN SELVA results?

The Palvella conference call is scheduled for February 24, 2026 at 8:00am ET. According to the company, a live webcast with slides and a phone option will be available, followed by a replay archived on the website.

How can investors access the PVLA webcast and replay for the SELVA topline announcement?

Investors can access the live webcast via the Events & Presentations section of Palvella’s website or registration link for dial-in details. According to the company, a replay will be available about two hours after the call and archived for 90 days.

What is being discussed on Palvella's call about QTORIN 3.9% rapamycin gel (PVLA)?

The call will discuss topline efficacy and safety results from the Phase 3 SELVA trial in microcystic lymphatic malformations. According to the company, the presentation will include slides and management commentary about those topline findings.

Will Palvella (PVLA) provide slides or supplemental materials with the SELVA topline call?

Yes. The company said the live webcast will include slides accessible via its Events & Presentations webpage. According to Palvella, slide materials will accompany the webcast and replay for investor review.